The identification and correction of pseudohypercalcemia

Area of Science:

• Biochemistry
• Clinical Medicine
• Hematology

Background:

• Monoclonal gammopathy can present with unexplained hypercalcemia, sometimes without clear clinical signs.
• A subset of patients (2.4%) with monoclonal gammopathy exhibit atypical hypercalcemia, with some cases suggesting pseudohypercalcemia due to normal ionized calcium levels.

Purpose of the Study:

• To identify factors contributing to pseudohypercalcemia in monoclonal gammopathy.
• To develop and validate a new formula for correcting calcium levels based on globulin for improved clinical diagnosis.

Main Methods:

• Observational study of 110 monoclonal gammopathy patients, with an additional 33 for validation.
• Univariate and multivariate logistic regression to identify risk factors for pseudohypercalcemia.
• Development of a globulin-corrected calcium formula using multiple linear regression and validation with paired t-test and Youden index.

Main Results:

• Elevated globulin levels (≥61 g/L) were identified as a significant risk factor for pseudohypercalcemia.
• A novel formula incorporating albumin and globulin demonstrated superior diagnostic accuracy (Youden index 0.906) compared to traditional methods.
• Monoclonal immunoglobulin types, except light chains, showed similar tendencies for pseudohypercalcemia, with linear correlations observed between IgA, IgG, IgM, and bound calcium.

Conclusions:

• Elevated globulin is confirmed to impact serum total calcium, with a threshold of ≥61 g/L aiding in pseudohypercalcemia diagnosis.
• The newly developed globulin-corrected calcium formula offers improved accuracy in diagnosing hypercalcemia in monoclonal gammopathy patients.
• Monoclonal immunoglobulin light or heavy chains alone do not appear to cause pseudohypercalcemia.